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ABSTRACT Carbapenem-resistant Enterobacteriaceae are urgent threats to global
human health. These organisms produce -lactamases with carbapenemase activity,
such as the metallo--lactamase NDM-1, which is notable due to its association with
mobile genetic elements and the lack of a clinically useful inhibitor. Here we exam-
ined the ability of copper to inhibit the activity of NDM-1 and explored the potential
of a copper coordination complex as a mechanism to efficiently deliver copper as an
adjuvant in clinical therapeutics. An NDM-positive Escherichia coli isolate, MS6192,
was cultured from the urine of a patient with a urinary tract infection. MS6192 was resis-
tant to antibiotics from multiple classes, including diverse -lactams (penicillins, cephalo-
sporins, and carbapenems), aminoglycosides, and fluoroquinolones. In the presence of
copper (range, 0 to 2 mM), however, the susceptibility of MS6192 to the carbapenems
ertapenem and meropenem increased markedly. In standard checkerboard assays, cop-
per decreased the MICs of ertapenem and meropenem against MS6192 in a dose-
dependent manner, suggesting a synergistic mode of action. To examine the inhibitory
effect of copper in the absence of other -lactamases, the blaNDM-1 gene from MS6192
was cloned and expressed in a recombinant E. coli K-12 strain. Analysis of cell extracts
prepared from this strain revealed that copper directly inhibited NDM-1 activity, which
was confirmed using purified recombinant NDM-1. Finally, delivery of copper at a low
concentration of 10 M by using the FDA-approved coordination complex copper-
pyrithione sensitized MS6192 to ertapenem and meropenem in a synergistic manner.
Overall, this work demonstrates the potential use of copper coordination complexes as
novel carbapenemase adjuvants.
KEYWORDS metallo--lactamase, carbapenem-resistant Enterobacteriaceae, copper,
urinary tract infection, antibiotic resistance
Carbapenems (ertapenem, doripenem, imipenem, and meropenem) are -lactamantibiotics with broad-spectrum activity (1, 2). They are generally used as a last
resort for treating infections caused by cephalosporin-resistant Enterobacteriaceae.
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Hence, it is alarming that resistance to carbapenems, primarily in Gram-negative
bacteria, has now emerged and disseminated worldwide, leading to high rates of
treatment failure and increased complications (3–6). Carbapenem-resistant Enterobac-
teriaceae (CRE), including Escherichia coli and Klebsiella pneumoniae, are frequently
associated with hospital-acquired lung infections, urinary tract infections (UTIs), blood-
stream infections, and device-related infections, with UTIs, including catheter-
associated UTIs, the most common infections acquired in nosocomial settings (7).
Combined with the asymptomatic carriage of CRE (8, 9) and the potential for trans-
mission of resistance via mobile genetic elements (10, 11), it is not surprising that CRE
are recognized as some of the most urgent threats to global human health today (12).
Mechanisms of carbapenem resistance in CRE frequently involve the expression of
carbapenemases, which are broad-spectrum -lactamases that hydrolyze carbapenems
with high catalytic efficiency. These carbapenemases are diverse and include the
Ambler class A (e.g., KPC) and class D (e.g., OXA-48) serine hydrolases, as well as class
B metallo--lactamases (MBLs) (e.g., VIM, IMP, and NDM) (13). One approach to combat
carbapenem resistance would be to develop adjuvants that inhibit carbapenemases,
thus restoring susceptibility to carbapenems and ultimately extending the use of these
antibiotics. For the serine-dependent lactamases, this strategy is best exemplified by
the clinical use of clavulanic acid and tazobactam as -lactam adjuvants that inhibit the
activity of extended-spectrum -lactamases (ESBLs) and restore the susceptibility of
ESBL-positive strains to -lactams (14). However, such inhibitors are ineffective against
MBLs (15, 16). MBLs require up to two zinc ions for activity and thus they are inhibited
by reagents that disrupt zinc binding, through either complete chelation (e.g., EDTA) or
partial coordination (e.g., thiol-containing compounds) (14, 15, 17). Despite their effec-
tiveness in vitro, these inhibitors have not proven to be clinically useful (14, 15).
Here we present evidence for a possible approach to inactivate MBLs with copper
ions. Using the New Delhi metallo--lactamase 1 (NDM-1) enzyme as our model, we
show that copper ions inhibit the activity of this MBL in vitro and enhance the
susceptibility of MBL-positive isolates of E. coli to carbapenems. Using pyrithione, a
FDA-approved antifungal agent that exerts an antimicrobial effect by acting as a copper
delivery molecule (18), we also provide proof of the concept that copper coordination
complexes have the potential to be used clinically as carbapenem adjuvants.
RESULTS
Copper ions potentiate the antibacterial activity of carbapenems against NDM-
positive E. coli. MS6192 is a NDM-positive, carbapenem-resistant isolate of E. coli that
is also resistant to cephalosporins, fluoroquinolones, and aminoglycosides (Table 1). To
assess the effects of copper ions on this antibiotic resistance profile, we first employed
a modified disc diffusion assay on solid medium containing copper sulfate (0 to 2 mM).
At those concentrations, copper alone did not inhibit the growth of MS6192 but it led
to dose-dependent increases in the zones of clearance around carbapenem (ertapenem
and meropenem) discs (Table 2). This potentiating effect of copper was also observed
with 11 additional NDM-positive clinical isolates (see Table S1 in the supplemental
material), but only strain MS6192 was selected for further study. The zones of clearance
around other antibiotic discs, including other -lactams, remained unchanged (Table 2),
suggesting that the potentiating effect of copper was specific to carbapenems. Stan-
dard checkerboard assays confirmed that addition of copper decreased the MICs of
carbapenems against strain MS6192 in a dose-dependent manner (Fig. 1A). The frac-
tional inhibitory concentration (FIC) index values were 0.17  0.13 for the combination
of copper and ertapenem and 0.11  0.06 for the combination of copper and
meropenem, suggesting that the interactions between copper and carbapenems were
synergistic (FIC index values of 0.5) (Fig. S1A).
Copper ions inhibit the activity of NDM-1 carbapenemase. Excess copper ions
are known to inactivate a variety of metalloenzymes (19–22). Because the observed
potentiating effect of copper was specific to carbapenems (Table 2), we hypothesized
that this metal affected the activity of NDM-1. To test this idea, strain MS6192 was
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cultured without or with copper sulfate (2 mM) to mid-exponential phase, and total
-lactamase activities in cell extracts were measured using nitrocefin as the substrate.
As predicted, growth in copper-rich medium led to a decrease in lactamase activity (Fig.
2A). However, a partial reduction was achieved (50%) (Fig. 2A), likely because MS6192
possesses multiple -lactamase enzymes (NDM-1, CTX-M-15, and OXA-1), some of
which are not MBLs and thus may be insensitive to copper.
TABLE 1 Antibiotic resistance profile of E. coli strain MS6192
Antibiotic class and name MIC (g/ml)
-Lactams
Penicillins
Ampicillin 32
Amoxicillin-clavulanic acid 32
Ticarcillin-clavulanic acid 128
Piperacillin-tazobactam 128
Cephalosporins
Cefazolin (first generation) 64
Cefoxitin (second generation) 64
Ceftazidime (third generation) 64
Ceftriaxone (third generation) 64
Cefepime (fourth generation) 64
Carbapenems
Meropenem 16
Aminoglycosides
Amikacin 64
Gentamicin 16
Tobramycin 16
Fluoroquinolones
Norfloxacin 16
Ciprofloxacin 4
Others
Nitrofurantoin 128
Trimethoprim 16
Trimethoprim-sulfamethoxazole 32
TABLE 2 Effects of copper ions on the resistance of E. coli strain MS6192 to antibiotics, as
determined by disc diffusion assays
Antibiotic class and
name Amount (g)
Zone of clearance (mm)a
0 mM copper
sulfate
1 mM copper
sulfate
2 mM copper
sulfate
-Lactams
Carbapenems
Ertapenem 10 8 11 26
Meropenem 10 11 17 32
Penicillins
Ampicillin 10 7 7 7
Cephalosporins
Ceftriaxone 30 7 7 7
Cefotaxime 30 7 7 7
Monobactams
Aztreonam 30 7 7 7
Aminoglycosides
Gentamicin 10 7 7 7
Tobramycin 10 7 7 7
Fluoroquinolones
Ciprofloxacin 5 7 7 7
aValues are representative of three independent experiments. The diameter of the discs was 7 mm, and a
value of 7 mm indicates that no zone of clearance was observed around the disc.
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To simplify this analysis, we cloned the blaNDM-1 gene of MS6192 under an isopropyl-
-D-thiogalactopyranoside (IPTG)-inducible promoter and transformed this plasmid
(pSU2718::blaNDM-1) into the K-12 strain MG1655. The resulting NDM-positive recom-
binant strain MS8485 was resistant to penicillin, cephalosporins, and carbapenems (Fig.
3), as expected from the broad-spectrum activity of NDM-1. Disc diffusion and check-
erboard assays confirmed that addition of copper to the culture medium restored the
susceptibility of MS8485 to all -lactams to levels that were comparable to those of
MG1655 (Fig. 1 and 3). The mode of action was again synergistic, with FIC index values
of 0.11  0.03 for ertapenem and 0.11  0.04 for meropenem (Fig. S1B). These results
were consistent with loss of NDM-1 activity in the presence of copper. Indeed, cell
extracts of copper-treated MS8485 did not display appreciable NDM-1 activity when
tested using nitrocefin as the substrate (Fig. 2B).
As a control, we measured the production of NDM-1 in MS8485 by immunoblot
analysis. Expression of the blaNDM-1 gene in strain MS8485 was induced by IPTG but, to
our surprise, copper treatment led to a reduction in the amount of NDM-1 enzyme (Fig.
S2). This may account, at least partially, for the loss of -lactamase activity in copper-
treated cells (Fig. 2B). Similar observations were made using strain MS6192 (Fig. 2A; also
see Fig. S2), but the blaNDM-1 gene in this strain is expressed from its native promoter.
It is possible that copper exerts an effect at the step of enzyme folding, maturation, or
secretion.
FIG 1 Effects of subinhibitory amounts of copper ions (0 to 2.5 mM) on the MIC values of ertapenem (top)
and meropenem (bottom) against E. coli strains MS6192 (A), MS8485 (B), and MG1655 (C), as determined
by standard checkerboard assays. Data shown were from three independent replicates. A MIC value of
0 g/ml indicates that growth was inhibited in the absence of the carbapenem.
FIG 2 Effects of copper ions on -lactamase activity in E. coli strains MS6192 (A) and MS8485 (B). Bacteria
were cultured to the mid-exponential phase without (-Cu) or with (Cu) subinhibitory amounts of
copper (2 mM) and were lysed by sonication. As a negative control, MG1655 was also cultured without
any copper (Control). Lactamase activities were measured in cell extracts and averaged from three
independent replicates. Error bars represent standard deviations (SDs).
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Although our immunoblot assays confirmed the observed production (albeit re-
duced) of NDM-1 in copper-treated MS8485 (Fig. S2), we did not detect appreciable
NDM-1 activity above background levels (Fig. 2B). Thus, we tested the possibility that
copper also directly inhibited the activity of NDM-1 by measuring its kinetic properties
in cell extracts of MS8485 prepared following culture in copper-free medium. Addition
of copper (0 to 80 M) to the reaction buffer led to a dose-dependent decrease in
NDM-1 activity (Fig. 4A). The data were best fitted to a noncompetitive model of
inhibition (R2  0.97) with an apparent inhibition constant (Ki) of 47  5 M in these
cell extracts (Fig. 4A; also see Fig. S3A). A noncompetitive mode of inhibition was confirmed
by repeating these measurements using purified recombinant NDM-1 (Fig. 4B; also see Fig.
S3B). A lower Ki of 3.7  0.3 M (R2  0.99) was obtained, confirming that copper
strongly inhibits NDM-1 activity. A noncompetitive mode of inhibition by Cu(II) with a
similar magnitude was recently reported for the MBL AIM-1 (23).
The susceptibility of NDM-positive E. coli to carbapenems is enhanced using a
copper coordination complex. Ionic copper salts are lipid insoluble and so are poorly
membrane permeable. As a consequence, high doses are often required to achieve
antibacterial effects in vitro (e.g., 2 mM copper sulfate in our assays), hampering the
development of copper-based antibiotics in clinical medicine. We and others have used
small (500-Da) lipophilic compounds with high binding affinities for copper to act
as membrane-permeable carriers of copper ions (24–26). These copper coordination
complexes are under investigation as clinical therapeutic agents (27–29), and some are
potent antibacterial agents, at least in vitro (24–26). One such carrier, pyrithione
(Fig. 5A), has been marketed for decades as an antifungal agent in health care and
FIG 3 Effects of subinhibitory amounts of copper ions (0 to 2 mM) on the resistance of E. coli strains MG1655 (A) and MS8485 (B) to
-lactam antibiotics, as determined by disc diffusion assays. Diameters of the zones of clearance were averaged from three independent
replicates. Error bars represent SDs. The diameter of the discs was 7 mm, and a value of 7 mm indicated that no zone of clearance was
observed around the disc.
FIG 4 Direct inhibitory effects of copper ions on NDM-1 activity. The activity of MS8485 cell extracts (A)
or purified NDM-1 (B) was measured in the presence of copper sulfate, using nitrocefin as the substrate.
The concentrations of copper sulfate are indicated to the right of each curve. Each data point was
averaged from three independent replicates. Error bars represent standard errors of the mean (SEMs).
Data were fitted to noncompetitive and competitive models of enzyme inhibition (see Fig. S3 in the
supplemental material).
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consumer products. Pyrithione is usually supplied in a zinc-coordinated form, but its
action relies on transmetalation by trace exogenous copper ions and subsequent
delivery of antimicrobial copper (18).
To determine whether pyrithione can deliver copper ions to CRE and inhibit NDM-1
carbapenemase activity, we repeated our checkerboard assays in the presence of
copper-loaded pyrithione (0 to 20 M). As anticipated, the copper-pyrithione complex
increased the susceptibility of MS6192 and MS8485 to ertapenem and meropenem (Fig.
5B and C). The FIC index values were 0.18  0.07 (ertapenem) and 0.13  0.05
(meropenem) for MS6192 and 0.28  0.11 (ertapenem) and 0.17  0.08 (meropenem)
for MS8485 (Fig. S4), again suggesting that the mode of interaction was synergistic.
Copper was required for this synergy, as zinc-loaded pyrithione had little effect on
carbapenem resistance (Fig. 5B and C). It must be noted that, in contrast to copper ions
(Fig. 1), copper-pyrithione did not decrease the MIC values of carbapenems against
MS8485 to MG1655 levels (Fig. 5). At 20 M, copper-pyrithione completely suppressed
the growth of E. coli even in the absence of carbapenems (Fig. 5B and C). Therefore, the
potentiating effect of copper-pyrithione is a combination of its direct antibacterial
action and the inhibition of carbapenemase activity.
DISCUSSION
The antibacterial properties of copper have been recognized for millennia, and
simple ionic salts and complexes of copper were used to control bacterial infections in
the preantibiotic age (30). It is now established that excess copper ions poison bacterial
cells by inactivating key metalloenzymes, particularly those containing solvent-
accessible iron (19) and zinc (20). This is a consequence of the high relative affinity of
copper for these metal binding sites, which leads to metal exchange and displacement
of the cognate but more weakly binding metals (21). Here we showed that copper ions,
as Cu(II), can directly inactivate the metalloenzyme NDM-1. The precise mechanism
remains to be elucidated, but we propose that copper may disrupt binding of one or
FIG 5 Structure of copper-pyrithione complex (A) and the effects of subinhibitory amounts of copper-
pyrithione (0 to 20 M) (solid lines) and zinc-pyrithione (0 to 20 M) (dotted lines) on the MIC values of
ertapenem (B) and meropenem (C) against E. coli strains MS6192, MS8485, and MG1655, as determined
by standard checkerboard assays. Data shown were from three independent replicates. A MIC value of
0 g/ml indicates that growth was inhibited in the absence of added carbapenem. PYT, pyrithione.
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both of the zinc ions in the active site of NDM-1. This model is in agreement with a
recent study using the MBL AIM-1, which demonstrated that two Cu(II) ions bind to the
enzyme in close proximity (23). Alternatively, copper ions may bind to an allosteric site
outside the zinc-containing pocket. Both scenarios (summarized in Fig. 6) would be
consistent with the observed noncompetitive mode of enzyme inhibition, but detailed
structural and biochemical studies of the purified enzyme will be required to describe
the molecular basis of this inhibition.
Our immunoblot results indicated that copper may also affect the synthesis, mat-
uration (enzyme folding and zinc site assembly), or stability of NDM-1. Although NDM-1
is anchored to the outer membrane and secreted in outer membrane vesicles (31), it is
folded and metallated in the periplasm (32). These latter processes are universal to all
MBLs, including the VIM, IMP, and AIM carbapenemases, and they can also be disrupted
by excess copper (23, 33, 34). Indeed, a recent study suggested that NDM-1 enzymes
lacking the zinc centers are degraded in the cell (31).
In our experiments, copper was supplied in the growth medium as Cu(II) ions.
Inactivation of NDM-1 via the various potential routes described above would rely on
diffusion of these Cu(II) ions into the cytoplasm, periplasm, or outer membrane vesicles.
However, the concentration of copper required to restore susceptibility of MS6192 to
carbapenems (2 mM) in our study was high and unlikely to be tolerated physiolog-
ically. We were able to reduce this amount by 2 orders of magnitude to 10 M by
coordinating the copper ion to pyrithione, a FDA-approved antifungal agent that acts
as a membrane-permeable carrier of copper. Pyrithione and its zinc-coordinated form
are currently approved for topical administration. While most formulations in consumer
goods and health care products contain up to 2% of this compound, it is not known
whether the copper form is equally tolerated. However, a variety of other copper
carriers are currently being investigated for their therapeutic potential (24–26). The
results presented here provide an early proof of concept that ligand- or carrier-
mediated delivery of copper ions to bacterial cells, in this case to target NDM-1
carbapenemase activity, is possible. Our data also support an emerging role of metal
ions in enhancing the action of antibiotics. For example, silver can potentiate vanco-
mycin activity by disrupting multiple bacterial cellular processes, including disulfide
bond formation, metabolism, and iron homeostasis (35).
The ability of copper to inhibit NDM-1 carbapenemase activity also provides an oppor-
tunity to develop therapeutic agents that work in concert with the host innate immune
system. Although the availability and location of copper in the human body are tightly
FIG 6 General schematic of the effects of copper ions on NDM-1 activity. Our data indicate that copper
can directly inhibit the carbapenemase activity of NDM-1 and also may affect NDM-1 synthesis,
maturation, or stability. Cu(II) and Zn(II) ions are depicted by black circles and light gray circles,
respectively. IM, inner membrane; OM, outer membrane; OMV, outer membrane vesicle.
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regulated, copper is mobilized in response to inflammation, leading to increased copper
concentrations at the site of infection. For instance, mobilization of copper occurs in
infected macrophages (36). Infections involving a variety of pathogens also result in
increased copper levels in the serum, liver, and spleen of animals (37, 38). In the case of E.
coli, particularly uropathogenic strains, it has been shown that copper levels are elevated (to
0.3 M) in the urine of patients with UTIs, compared to healthy controls (39, 40). Thus,
delivery of membrane-permeable copper carriers such as pyrithione into the urinary tract
may allow us to exploit this host-derived copper and enhance its action against CRE.
MATERIALS AND METHODS
Bacterial strains, reagents, and culture conditions. E. coli MS6192 is a NDM-1-positive strain that
was isolated from the urine of a patient with a UTI. E. coli MG1655 is a K-12 strain and is susceptible to
all antibiotics. All strains were propagated from frozen glycerol stocks on Luria-Bertani (LB) agar at 37°C.
Liquid cultures were prepared in LB broth and grown at 37°C with shaking at 200 rpm. Antibiotic discs
(Sensi-Discs) were purchased from BD Biosciences (Australia). Copper(II) sulfate (product no. C8027),
zinc(II) pyrithione (product no. H6377), ertapenem sodium (product no. SML1238), and meropenem
trihydrate (product no. M2574) were purchased from Sigma (Australia). Stocks of reagents were prepared
in deionized water except for zinc pyrithione, which was dissolved in dimethyl sulfoxide (DMSO).
Copper(II) pyrithione was prepared by adding equimolar amounts of copper sulfate to a solution of
zinc(II) pyrithione.
Cloning and expression of the blaNDM-1 gene in MG1655. The blaNDM-1 gene from MS6192 was
amplified with primers 7414 (5=-TGATAAGGATCCATTCAGCTTTCACCCATTGG-3=) and 7415 (5=-TCGAAAA
AGCTTGATGGCAGATTGGGGGTGA-3=) and cloned between the BamHI and HindIII sites of pSU2718. The
resulting plasmid, pSU2718::blaNDM-1, was transformed into E. coli MG1655 by electroporation to
generate the NDM-1-positive strain MS8485. MS8485 was cultured in the presence of chloramphenicol
(30 g/ml) and IPTG (0.1 mM) to maintain the plasmid and to promote NDM-1 expression, respectively.
Antibiotic susceptibility assays. The antimicrobial susceptibility profile of MS6192 was determined
using the Vitek 2 automated AST-N426 card (bioMérieux). The Etest was used to determine MICs for
meropenem, imipenem, and ertapenem. Disc diffusion assays were performed by seeding LB agar
containing copper sulfate (0 to 2 mM) or copper pyrithione (0 to 20 M) with bacterial suspensions at
an optical density at 600 nm (OD600) of 0.18 (1.5  108 CFU/ml, equivalent to a McFarland standard of
0.5). Zones of clearance around antibiotic discs were measured after incubation at 37°C for 24 h.
Checkerboard assays were also performed in LB broth. Bacterial suspensions were prepared to an OD600
of 0.001 (5  105 CFU/ml), and exactly 100 l was dispensed into each well of a U-bottomed, 96-well,
microtiter plate. To each well were also added 50 l of LB broth containing ertapenem or meropenem
(0 to 64 g/ml) and 50 l of LB broth containing copper sulfate (0 to 5 mM) or copper pyrithione (0 to
20 M). Turbidity in each well was measured using a microtiter plate reader after incubation at 37°C for
24 h. The MIC was defined as the lowest concentration of agent that completely inhibited bacterial
growth. The FIC for each agent was defined as its MIC in combination divided by its MIC alone. The FIC
index was the sum of the FIC values for the two agents.
Overexpression and purification of recombinant NDM-1. To obtain the pure NDM-1 enzyme, the
coding sequence for NDM-1 (residues 27 to 270) was amplified from strain MS6192 using primers 7456
(5=-TACTTCCAATCCAATGCGATGCCCGGTGAAATCC-3=) and 7457 (5=-TTATCCACTTCCAATGTCAGCGCAGC
TTGTCG-3=) containing ligation-independent cloning (LIC) overhangs. The gene product was cloned into
the pAL vector encoding a N-terminal His6 tag followed by a thioredoxin (TRX) domain and a TEV
protease cleavage site. NDM-1 was expressed overnight at 37°C in the E. coli BL21(DE3) host in the
presence of 0.5 mM IPTG. Cells were lysed in Tris-Cl buffer (25 mM Tris, 150 mM NaCl, 20 M ZnCl2 [pH
7.5]) by sonication, and NDM-1 protein was purified on a Ni-nitrilotriacetic acid (NTA) HisTrap column (GE
Healthcare) by using the same buffer and a gradient of 0 to 400 mM imidazole. The N-terminal His6 tag
was cleaved with TEV protease and repurified by elution from a Ni-NTA HisTrap column.
Assays of NDM-1 activity. To prepare cell extracts, bacteria (50 ml) were cultured without or with
copper sulfate (2 mM) to the mid-exponential phase (OD600 of 0.4 to 0.5), centrifuged (5,000  g for
10 min), washed with phosphate-buffered saline (PBS), resuspended in 500 l of HEPES buffer (50 mM
HEPES [pH 7.4]), lysed by sonication (five 10-s bursts at 10 W each), and clarified by centrifugation
(20,000  g for 5 min). -Lactamase activity in these cell extracts was measured by monitoring the
hydrolysis of nitrocefin (0 to 250 M) in HEPES buffer (50 mM HEPES [pH 7.4]) at 35°C. Copper sulfate (0
to 100 M) was added to the nitrocefin solution immediately before addition of the cell extracts to
initiate hydrolysis. Absorbance values at 485 nm ( of 17.5 mM	1 cm	1) were monitored continuously for
2 min in a spectrophotometer. Initial rates (up to 30 s) were normalized to total protein concentrations
as determined by the bicinchoninic acid (BCA) assay. Data were fitted to the Michaelis-Menten equation,
which incorporates terms describing either noncompetitive or competitive inhibition, using the software
package Prism 7 (GraphPad).
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